Clinical trials: Stage IIA Prostate Cancer
Hormone Refractory Prostate Cancer
RNActive®-Derived Therapeutic Vaccine
This is a Phase I/IIa open, uncontrolled, prospective study, to be conducted in an out-patient setting. The present study is one of two clinical trials of the RNActive®-derived vaccine CV9103 being conducted concurrently in the…
- Trial name
- NCT00906243
- Testing
- CV9103
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
Watchful Living in Improving Quality of Life in Participants With Localized Prostate Cancer on Active Surveillance and Their Partners
This pilot trial studies how well Watchful Living works in improving quality of life in participants with prostate cancer that has not spread to other parts of the body who are on active surveillance and their partners.
- Conditions
- Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8
- Trial name
- NCT03575832
- Testing
- Counseling, Informational Intervention, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Diet and PSA Levels in Patients With Prostate Cancer
RATIONALE: The amount of fat, fiber, soy, fruits, vegetables, vitamin E, and green tea in the diet may affect androgen metabolism in men. This may affect PSA level in patients with prostate cancer.
- Trial name
- NCT00003367
- Testing
- green tea, soy protein isolate, vitamin E
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors
This phase I trial studies the side effects and best dose of SOR-C13 in treating patients with solid tumors that have spread to other places in the body (advanced) and does not respond to treatment.
- Conditions
- Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Ovarian Carcinoma, Refractory Pancreatic Carcinoma
- Trial name
- NCT03784677
- Testing
- TRPV6 Calcium Channel Inhibitor SOR-C13
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
High-Intensity Focused Ultrasound Therapy in Treating Patients With Localized Prostate Cancer
RATIONALE: High-intensity focused ultrasound energy may be able to kill tumor cells by heating them without affecting normal tissue.
- Trial name
- NCT00561262
- Testing
- questionnaire administration, high-intensity focused ultrasound ablation, quality-of-life assessment
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University College London Hospitals
Locally Recurrent Prostate Cancer
An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy
The purpose of this study is to determine the therapeutic activity of different concentrations of PRX302 at increasing volumes and/or number of deposits per gram of prostate.
- Trial name
- NCT00686088
- Testing
- PRX302
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sophiris Bio Corp
Prostate Cancer
Comparing Two Sets of Bladder-Filling Instructions in Treating Patients Undergoing Radiation Therapy For Prostate Cancer. ICORG 05-04
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00949338
- Testing
- pre-procedural preparation
- Where
- Ireland
- Volunteers
- 183 people
- Sponsor
- Cancer Trials Ireland
Bladder Cancer, Triple Negative Breast Cancer
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours.
- Conditions
- Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer
- Trial name
- NCT05057013
- Testing
- HMBD-001, HMBD-001 and enzalutamide
- Where
- 4 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- Cancer Research UK
Prostate Cancer
Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as exisulind, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00078910
- Testing
- exisulind, conventional surgery, neoadjuvant therapy
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Hormone Therapy Followed By Internal Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as goserelin, leuprolide, flutamide, or bicalutamide may stop the adrenal glands from producing androgens.
- Trial name
- NCT00032006
- Testing
- brachytherapy, radiation therapy
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adenocarcinoma of the Prostate
Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer
Open-label, dose rising, Phase IIa trial of intratumorally-injected NanoPac® 6, 10, or 15 mg/mL in subjects with prostate cancer scheduled for prostatectomy.
- Trial name
- NCT03077659
- Testing
- NanoPac®
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- NanOlogy, LLC
Prostate Cancer
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT01368588
- Testing
- three-dimensional conformal radiotherapy, intensity modulated radiotherapy, Brachytherapy
- Where
- 478 sites in United States, Canada and 4 more
- Volunteers
- 2,590 people
- Sponsor
- Radiation Therapy Oncology Group
Malnutrition, Prostate Cancer
Diet and Exercise-Based Counseling Program Compared With a Standard Counseling Program in Patients With Early-Stage Prostate Cancer
RATIONALE: An individualized, computer-designed health program may promote changes in diet and physical activity and may improve quality of life in patients who have early-stage prostate cancer.
- Trial name
- NCT00044980
- Testing
- nutritional support, quality-of-life assessment
- Where
- United States
- Sponsor
- Duke University
Prostatic Neoplasms, Castration-Resistant
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
- Trial name
- SECuRE (NCT04868604)
- Testing
- 64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer
This is a Phase Ib/IIa Study of Cabazitaxel plus Bavituximab in patients with castration-resistant prostate cancer (CRPC). The current study is designed to determine if the addition of bavituximab to cabazitaxel will improve…
- Trial name
- NCT01335204
- Testing
- Cabazitaxel plus bavituximab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Medical University of South Carolina
Prostate Cancer
Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
RATIONALE: Patient abstract not available PURPOSE: Patient abstract not available
- Trial name
- NCT00767286
- Testing
- flutamide, goserelin acetate, low-LET cobalt-60 gamma ray therapy
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Ultrasound in Treating Patients With Prostate Cancer Confined to the Prostate
RATIONALE: Highly focused ultrasound energy may be able to kill cancer cells by heating the tumor without affecting the surrounding tissue.
- Trial name
- NCT00030290
- Testing
- high-intensity focused ultrasound ablation
- Where
- United States
- Sponsor
- Focus Surgery
Prostate Cancer
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Bicalutamide and goserelin may fight prostate cancer by reducing the production of testosterone.
- Trial name
- NCT00021450
- Testing
- bicalutamide, goserelin acetate, adjuvant therapy
- Where
- 20 sites in Belgium, Cyprus and 9 more
- Volunteers
- 819 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Adenocarcinoma of the Prostate, Bone Metastases
A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine
This pilot clinical trial studies fludeoxyglucose F18 (FDG)-positron emission tomography (PET) in imaging patients with prostate cancer treated with ranolazine.
- Conditions
- Adenocarcinoma of the Prostate, Bone Metastases, Soft Tissue Metastases, Stage IIA Prostate Cancer
- Trial name
- NCT01992016
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Colorado, Denver
Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
Daily, Long-Term Intermittent Fasting for the Prevention of PSA-Recurrence in Patients With Localized Prostate Cancer After Radical Prostatectomy
This early phase I trial studies the feasibility of a daily, long-term intermittent fasting routine in preventing or delaying a rise in prostate specific antigen (PSA) levels in patients with prostate cancer that has not spread…
- Conditions
- Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8
- Trial name
- NCT04288336
- Testing
- Food Diary, Preventative Dietary Intervention, Questionnaire Administration
- Where
- United States
- Sponsor
- Mayo Clinic